hutch-med.com (HCM): Debt to Equity

This daily price chart for HUTCHMED (China) Limited (HCM) shows the separate_debt_total_eq metric at 0.07. HUTCHMED (China) Limited develops anti-tumor agents, leveraging exclusive patents and low chemical synthesis costs to drive exponential profit growth. The business contends with skepticism toward Chinese developments and pressure from Western pharma behemoths. Meanwhile, the company's plants are being modernized to meet international GMP standards, operating without interruption.

For long-term risk management, it is critical to assess business dependence on borrowed funds by comparing all liabilities against net assets. By analyzing total debt relative to equity, an investor determines the financial stability of HUTCHMED (HCM), whose global reputation in oncology enables it to attract capital on favorable terms, minimizing insolvency risks while scaling innovative developments.